Entrectinib has demonstrated both in vitro and in vivo efficacy in inhibiting cancer cell lines across multiple tumor types carrying NTRK, ROS1, or ALK fusions. Additionally, it achieves steady ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback